Equillium Inc and Ono Pharmaceutical Co Ltd to Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab Call Transcript

Dec 06, 2022 / 01:30PM GMT
Operator

Welcome and thank you for joining us this morning for Equillium's announcement regarding their exclusive option and asset purchase agreement with Ono Pharmaceuticals for the development and commercialization of itolizumab.

Presenting this morning, is Mr. Jason Keyes, Chief Financial Officer of Equillium; Mr. Bruce Steel, Chief Executive Officer of Equillium; and Dr. Stephen Connelly, Chief Scientific Officer of Equillium, will also join for Q&A following the presentation.

Before we begin, I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors. This include those discussed in the Risk Factors section in the company's most recent annual and quarterly reports, as well as other reports filed with the SEC. I'll remind you that this call is being recorded and a replay will be available on the company's website

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot